Back
Day Range
$17.86
$18.84
52-Week Range
$14.87
$24.89
Volume
503,611
50D / 200D Avg
$19.33
/
$19.03
Prev Close
$18.01
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -7.4 | 0.4 |
| P/B | 1.1 | 2.9 |
| ROE % | -14.2 | 3.8 |
| Net Margin % | -3.5 | 3.9 |
| Rev Growth 5Y % | -9.0 | 10.0 |
| D/E | 1.3 | 0.2 |
Insider Trading Activity
11 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 15, 2026 |
Grace Caroline
Chief Executive Officer
|
other | 92,661 | — | — |
| Jan 15, 2026 |
Grace Caroline
Chief Executive Officer
|
grant | 129,923 | — | — |
| Jan 15, 2026 |
Hagan Mark Christopher
Chief Information and Digital
|
other | 49,530 | — | — |
| Jan 15, 2026 |
Hagan Mark Christopher
Chief Information and Digital
|
grant | 73,656 | — | — |
| Jan 15, 2026 |
Laughlin Whitney M
Chief Legal Officer
|
other | 20,616 | — | — |
| Jan 15, 2026 |
Laughlin Whitney M
Chief Legal Officer
|
grant | 39,282 | — | — |
| Jan 15, 2026 |
Scott Brian M.
CFO/COO
|
other | 30,121 | — | — |
| Jan 15, 2026 |
Scott Brian M.
CFO/COO
|
grant | 40,920 | — | — |
| May 2, 2025 |
Jones Daphne E
Director
|
grant | 8,325 | — | — |
| May 2, 2025 |
Trent-Adams Sylvia
Director
|
grant | 8,325 | — | — |
| Apr 19, 2025 |
Trent-Adams Sylvia
Director
|
other | 6,038 | — | — |
Key Takeaways
Revenue declined -9.01% annually over 5 years
Generating 233.83M in free cash flow
PEG of 0.18 suggests growth is underpriced
Capital efficient — spends only 1.30% of revenue on capex
ROIC of 1.72% — low return on invested capital
Interest coverage of 0.73× — tight debt servicing
Growth
Revenue Growth (5Y)
-9.01%
Revenue (1Y)-8.49%
Earnings (1Y)N/A
FCF Growth (3Y)-6.38%
Quality
Return on Equity
-14.19%
ROIC1.72%
Net Margin-3.51%
Op. Margin1.21%
Safety
Debt / Equity
1.25
Current Ratio0.94
Interest Coverage0.73
Valuation
P/E Ratio
-7.43
P/B Ratio1.11
EV/EBITDA44.62
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -8.49% | Revenue Growth (3Y) | -15.11% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -9.01% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2.73B | Net Income (TTM) | -95.70M |
| ROE | -14.19% | ROA | -4.57% |
| Gross Margin | 22.93% | Operating Margin | 1.21% |
| Net Margin | -3.51% | Free Cash Flow (TTM) | 233.83M |
| ROIC | 1.72% | FCF Growth (3Y) | -6.38% |
| Safety | |||
| Debt / Equity | 1.25 | Current Ratio | 0.94 |
| Interest Coverage | 0.73 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -7.43 | P/B Ratio | 1.11 |
| P/S Ratio | 0.26 | PEG Ratio | 0.18 |
| EV/EBITDA | 44.62 | Dividend Yield | 0.00% |
| Market Cap | 710.61M | Enterprise Value | 1.48B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.73B | 2.98B | 3.79B | 5.24B | 3.98B |
| Net Income | -95.70M | -146.98M | 210.68M | 444.05M | 327.39M |
| EPS (Diluted) | -2.48 | -3.85 | 5.36 | 9.90 | 6.81 |
| Gross Profit | 626.19M | 919.38M | 1.25B | 1.72B | 1.31B |
| Operating Income | 33.17M | -102.67M | 338.43M | 647.10M | 478.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.09B | 2.42B | 2.92B | 2.89B | 3.13B |
| Total Liabilities | 1.45B | 1.71B | 2.09B | 1.84B | 1.97B |
| Shareholders' Equity | 642.11M | 706.62M | 831.26M | 1.04B | 1.16B |
| Total Debt | 803.20M | 1.10B | 1.35B | 860.96M | 867.07M |
| Cash & Equivalents | 33.97M | 10.65M | 32.94M | 64.52M | 180.93M |
| Current Assets | 545.38M | 594.92M | 841.69M | 1.09B | 1.35B |
| Current Liabilities | 577.61M | 545.79M | 656.12M | 857.93M | 969.39M |